Recombine Announces Launch of Its CarrierMap™ Carrier Screening Test Through Sequenom

NEW YORK--(BUSINESS WIRE)--

Recombine, Inc., a clinical genetic testing company dedicated to helping patients and providers make informed healthcare decisions, announced a partnership with Sequenom Laboratories, a wholly owned subsidiary of Sequenom, Inc. SQNM, a leading life sciences company, to expand access to Recombine's CarrierMap test beyond the fertility and in-vitro fertilization (IVF) setting. Sequenom will market the test under the name HerediT^® UNIVERSAL.

"We are excited to collaborate with Sequenom Laboratories, the market leader in noninvasive prenatal testing, to bring our CarrierMap expanded carrier screening technology to the OBGYN and maternal fetal medicine space," said Alexander Bisignano, Chief Executive Officer of Recombine, Inc. "This strategic alliance will help us reach more patients, and enable them to use comprehensive genetic testing and counseling services to make informed decisions in family planning."

The CarrierMap test is a comprehensive carrier screen for more than 250 genetic diseases for patients and gamete donors of all ethnicities. Current carrier screening options are limited to single gene testing or tests that can identify approximately 100 hereditary conditions.

"Though individually rare, genetic disorders are collectively common and are a significant cause of childhood mortality," said James Grifo, M.D., Ph.D., Program Director of New York University (NYU) Fertility Center. "CarrierMap provides an opportunity to look beyond a patient's family history or ethnic predispositions to particular diseases, which is increasingly important in our multiethnic society."

"We look forward to partnering with Recombine, a leader in the in-vitro fertilization marketplace, to enter the universal carrier screening market" said William Welch, President and Chief Executive Officer of Sequenom, Inc. "The launch of a comprehensive test like HerediT UNIVERSAL reinforces our goal to deliver solutions that provide physicians with the broadest range of genetic information possible for their patients."

About Sequenom

Sequenom, Inc. SQNM is committed to enabling healthier lives through the development of innovative products and services. The Company serves patients and physicians by providing early patient management information.

About Sequenom Laboratories

Sequenom Laboratories, a CAP-accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests, with a focus principally on prenatal care. Branded under the names HerediT^®, MaterniT21^® PLUS, SensiGene^® and VisibiliT^™, these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, and maternal fetal medicine specialists. Sequenom Laboratories is changing the landscape in genetic diagnostics using proprietary cutting edge technologies. To learn how Sequenom is interpreting the genome for improving the lives of patients everywhere, visit www.sequenom.com and follow @SequenomLabs.

About Recombine, Inc.

Recombine is a clinical genetic testing company dedicated to helping patients and providers make informed decisions based on comprehensive and clinically actionable genetic testing results and in-depth genetic counseling. Recombine joins experts in genetics, fertility, and computer science with one goal in mind: to improve health outcomes with personalized genomic testing. CarrierMap is Recombine's expanded carrier screening platform for over 250 genetic diseases designed for patients and gamete donors of all ethnicities. To learn how Recombine is leveraging the unprecedented power of advanced technologies, visit www.recombine.com and follow @Recombine.